Medipure’s aim is to develop first class therapeutics with direct relevance to specifically targeted human diseases. We are actively pursuing collaborations with clinics, academia, and strategic partners in order to continually strengthen our proprietary portfolio through new R&D programs. These networks will help Medipure develop effective APIs and phytochemical-based pharmaceuticals with optimized therapeutic effects for specific illnesses. Our main areas of research focus are:
- Pain management
- Mood disorders and anxiety
- Nausea and appetite
- Palliative care
As our proprietary products advance through pre-clinical and clinical studies, the data they generate will allow Medipure to identify molecular mechanisms of action, as well as the necessary pharmacological evidence for dosage, safety, and efficacy. This will enable us to make informed decisions regarding which drug formulations to advance towards clinical trials.
Pain is defined as physical suffering or discomfort caused by illness or injury. Physical pain can be divided into two types, which can have either acute or chronic manifestations:
Nociceptive pain is pain caused by damage to tissues. This includes chronic pain such as visceral and deep somatic pain that may be caused by injury or is associated with carcinoma/sarcoma. Acute nociceptive pain includes post-operative pain or short-term pain caused by trauma.
Neuropathic pain refers to pain caused by damaged nerves and can result in the feeling of pain from normally non-painful stimuli. Neuropathic pain can be caused by spinal cord injury, multiple sclerosis, diabetes, or cancer (e.g., cancer on peripheral nerves or induced by chemotherapy).
Phytochemicals are capable of targeting a broad range of pharmacological mechanisms of pain, without having the psychotropic effects typically associated with many first-line medications. Furthermore, many current treatments of pain (e.g., opiates) have significant issues related to patient tolerability, dependency, and other negative side effects. Therefore, the development of pharmaceutical products containing specific phytochemical-driven API molecules holds great potential in the field of pain management.
Medipure Pharmaceutical MP-10X product line for pain management
Many types of cancers and the side effects of treatment (e.g., radiation, chemotherapy, surgery) manifest in various forms of acute and chronic nociceptive and neuropathic pain. Presently, we are developing specific molecule-based pharmaceuticals for pain management to be tested in pilot studies with cancer patients.
Many phytochemicals have demonstrable effects against various types of nociceptive and neuropathic pain. They can selectively regulate several receptor- and transporter-mediated biological functions inherent in the perception of pain* and many of them with analgesic qualities do not have the psychotropic.
The broad pharmacological profile of our APIs from phytochemicals highlights the promise of these molecules as therapeutics in pain management and Medipure’s MP-10X sublingual/transmucosal formulations are developed to target pain types through the activation of specific molecular mechanisms.
Our MP-10X proprietary formulations (MP-101, MP-102, MP-103, MP-104, MP-105) are in the product pipeline in order to identify lead candidate drug(s) for clinical trials and eventual launch to market. These formulations are delivered sublingually to ensure increased and consistent bioavailability across patients (bypassing first pass metabolism) while avoiding discomfort in patients who experience nausea and have difficulty swallowing or may vomit.
From the MP-10X line of formulations, Medipure will identify the best drug candidate with specifically optimized molecule ratios for synergism that mitigates the side effects often inherent in the treatment of pain.
*Modulation of CB1 and CB2 receptors and transient receptor potential cation channel (TRPV1, TRPV2, TRPA1, TRPM8) activation are well described targets of analgesia by phytochemicals in many types of pain. Furthermore, some molecules have the potential to regulate pain through interactions with α3 glycine receptors, G-coupled protein receptor GPR-55, serotonin receptors, adenosine A1 receptors, α2 adrenoceptors, and eCB (anandamide) reuptake. We are exploring non-phytochemical molecules for promising bioactivities and synergism with phytochemicals. For example, the selective CB2 agonist sesquiterpenoid has promising analgesic and anti-inflammatory effects.
Anxiety is a result of a combination of biological, psychological, and other individual factors. Neurochemical imbalances in γ-aminobutyric acid (GABA), serotonin, dopamine, epinephrine, and other neurotransmitter pathways in the brain can contribute to the development of anxiety. For example, serotonin appears to be specifically involved in feelings of well-being, and disruption in this pathway is highly related to anxiety and depression.
Medipure Pharmaceutical MP-20X product line for anxiety
People who have been diagnosed with cancer can experience a spectrum of anxiety disorders. Presently, we are developing specific phytochemical molecule-based pharmaceuticals for the treatment of anxiety to be tested in pilot studies in patients with cancer.
Endogenous CB1/CB2 receptor system plays a key role in regulating pathways related to anxiety and patients with mood and anxiety disorders generally have reduced levels of eCBs. Various phytochemicals at their non-psychoactive concentrations can exhibit anxiolytic properties by binding specifically to CB1 and 5-HT1A receptors that modulate anxiety-related pathways. Medipure’s MP-20X series of formulations are based on specific ratios of phytochemicals with APIs to act on CB1/5-HT1A receptors to exert anxiolytic effects. Medipure’s goal is to avoid issues related to dependency and tolerance that exists in current anxiolytic medications on the market, while ensuring optimal product safety and efficacy.
Our MP-20X proprietary formulations (MP-201, MP-202, MP-203, MP-204) are in the product pipeline in order to identify lead candidate drug(s) for clinical trials and eventual launch to market. These formulations are delivered sublingually to ensure increased and consistent bioavailability across patients (bypassing first pass metabolism) while avoiding discomfort in patients who experience nausea and have difficulty swallowing or may vomit.
From the MP-20X line of formulations, Medipure will identify the best drug candidate with specifically optimized molecule ratios for synergism that mitigates the side effects often inherent in the treatment of anxiety.